Solventum (NYSE:SOLV) Releases Quarterly Earnings Results, Beats Expectations By $0.64 EPS

Solventum (NYSE:SOLV) posted its quarterly earnings data on Wednesday. The company reported $2.55 EPS for the quarter, topping analysts’ consensus estimates of $1.91 by $0.64, FiscalAI reports. Solventum had a net margin of 17.33% and a return on equity of 23.51%. The firm had revenue of $2.21 billion during the quarter, compared to analyst estimates of $2.15 billion. During the same quarter last year, the business posted $1.69 EPS. The company’s revenue was up 2.2% on a year-over-year basis. Solventum updated its FY 2026 guidance to 7.100-7.200 EPS.

Here are the key takeaways from Solventum’s conference call:

• Solventum reported a strong Q2, with 9.5% organic sales growth, adjusted EPS of $2.55, and performance ahead of plan across all segments. Results benefited from approximately $125 million of ERP-related advanced orders and a $100 million tariff refund.
• Management raised 2026 guidance, including organic growth to 2.5%-3% excluding SKU exits (3.5%-4% on an ex-SKU basis), operating margin to 22.2%-22.7%, and EPS to $7.10-$7.20 from $6.40-$6.60.
• The ERP advanced orders are expected to mostly reverse in Q3, creating an anticipated 3%-4% decline in quarterly sales growth and a roughly $0.34 EPS headwind before a projected return to 3%-4% growth in Q4.
• Solventum is advancing the separation of its Health Information Systems business, believing an independent company or combination with a larger healthcare IT player could unlock value while allowing Solventum to focus on MedSurg and Dental. However, the process is still at an early stage and the transaction structure, timing, proceeds, and potential EPS impact remain uncertain.
• Acera continued to outperform, with revenue growth above 40% and gross margin above 80%, while management cited a multi-billion-dollar opportunity from underpenetrated growth drivers, including IV site management, wound care, sterilization, dental aesthetics, and AI-enabled coding.

Solventum Stock Down 5.0%

Shares of NYSE SOLV traded down $4.34 during mid-day trading on Thursday, reaching $83.13. 984,433 shares of the company’s stock traded hands, compared to its average volume of 1,410,645. The company has a debt-to-equity ratio of 0.96, a current ratio of 1.07 and a quick ratio of 0.75. The business has a 50-day simple moving average of $79.09 and a 200 day simple moving average of $74.36. The stock has a market cap of $14.40 billion, a P/E ratio of 10.15, a PEG ratio of 1.36 and a beta of 0.60. Solventum has a 1-year low of $62.38 and a 1-year high of $90.00.

Key Solventum News

Here are the key news stories impacting Solventum this week:

• Positive Sentiment: Q2 results exceeded expectations. Solventum reported adjusted earnings of $2.55 per share, well above the $1.91 consensus estimate, while revenue of $2.21 billion also topped forecasts. Revenue increased 2.2% year over year, with organic sales growth of 9.5%. Solventum Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Management raised its outlook. Solventum increased its fiscal 2026 adjusted EPS guidance to $7.10-$7.20, above the approximately $6.55-$6.58 analyst consensus, and also raised expectations for organic sales growth and free cash flow. Solventum outlines HIS separation and raises 2026 EPS guide
• Positive Sentiment: Analysts became more bullish. Piper Sandler raised its price target from $92 to $105 and assigned an “overweight” rating. Wedbush lifted its target from $94 to $101 with an “outperform” rating, while Stifel raised its target from $90 to $100 and now rates the stock “buy.” These targets imply roughly 19%-25% potential upside from recent trading levels. Analyst price-target changes
• Neutral Sentiment: Solventum plans to separate its Health Information Systems business. The move is intended to create a more focused medical-technology company while allowing the healthcare software unit to pursue its own growth strategy and potentially unlock shareholder value. Solventum Announces Intent to Separate its Health Information Systems Business
• Negative Sentiment: The separation introduces execution risk. The transaction is being pursued amid activist pressure and could involve restructuring costs, management distraction and uncertainty over the timing and terms of the divestiture. Investors may also be taking profits after the earnings beat and recent share-price strength, limiting the immediate benefit of the positive news. Solventum to hive off healthcare software business, raises profit forecast

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. KeyCorp raised their price target on Solventum from $93.00 to $102.00 and gave the stock an “overweight” rating in a research note on Thursday. BTIG Research lifted their target price on shares of Solventum from $91.00 to $95.00 and gave the company a “buy” rating in a research report on Thursday. Wells Fargo & Company dropped their price target on Solventum from $83.00 to $70.00 and set an “equal weight” rating for the company in a report on Wednesday, May 6th. Wedbush raised their target price on shares of Solventum from $94.00 to $101.00 and gave the company an “outperform” rating in a research note on Thursday. Finally, Mizuho set a $113.00 price objective on Solventum in a research note on Thursday. Seven equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Solventum presently has an average rating of “Hold” and an average price target of $91.64.

Institutional Investors Weigh In On Solventum

Several institutional investors and hedge funds have recently added to or reduced their stakes in SOLV. Boston Partners boosted its stake in shares of Solventum by 26.1% during the third quarter. Boston Partners now owns 4,630,300 shares of the company’s stock valued at $338,006,000 after purchasing an additional 959,543 shares during the period. Balyasny Asset Management L.P. bought a new stake in Solventum in the 3rd quarter worth $42,393,000. Raymond James Financial Inc. raised its stake in shares of Solventum by 116.5% during the third quarter. Raymond James Financial Inc. now owns 702,411 shares of the company’s stock valued at $51,276,000 after acquiring an additional 378,024 shares during the last quarter. Zimmer Partners LP bought a new stake in shares of Solventum in the third quarter worth about $20,075,000. Finally, AQR Capital Management LLC increased its holdings in Solventum by 82.0% during the 4th quarter. AQR Capital Management LLC now owns 469,288 shares of the company’s stock valued at $37,186,000 after purchasing an additional 211,440 shares during the period.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.